title: Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.
abstract: Antigen persistence in chronic infections and cancer upregulates inhibitory networks, such as the PD-1 and interleukin-10 (IL-10) pathways, that impair immunity and lead to disease progression. These pathways are attractive targets for immunotherapy, as demonstrated by recent clinical trials of PD-1/PD-L1 blockade in cancer patients. However, in HIV-1 infection not all subjects respond to inhibition of either pathway and the mechanistic interactions between these two networks remain to be better defined. Here we demonstrate that in vitro blockade of PD-L1 and/or IL-10Rα results in markedly different profiles of HIV-1-specific CD4 T cell restoration. Whereas PD-L1 blockade leads to balanced increase in gamma interferon (IFN-γ), IL-2, and IL-13 secretion, IL-10Rα blockade preferentially restores IFN-γ production. In viremic subjects, combined PD-L1/IL-10Rα blockade results in a striking 10-fold increase in IFN-γ secretion by HIV-1-specific CD4 T cells that is not observed in subjects with spontaneous (elite controllers) or therapy-induced control of viral replication. In contrast to the dramatic increase in IFN-γ production, concurrent blockade has a marginal additive effect on IL-2 production, IL-13 secretion, and HIV-1-specific CD4 T cell proliferation. IFN-γ produced by Thelper cells upregulates PD-L1, HLA I/II, and IL-12 expression by monocytes. The effect of combined blockade on IFN-γ was dependent on reciprocal reinforcement through IL-12. These studies provide crucial information on the different immunoregulatory qualities of PD-1 and IL-10 in progressive disease and link exhausted virus-specific CD4 T cells and monocytes in the regulation of IFN-γ and IL-12 secretion.
  
  
  OBJECTIVE
  Infection with HIV results in most people in uncontrolled viral replication and progressive weakening of the body defenses. In the absence of antiviral therapy, this process results in clinical disease, or AIDS. An important reason why HIV continues to multiply is that a population of white blood cells called CD4 T cells that targets the virus fails to work properly. At least part of this impairment is under the control of inhibitory mechanisms that can be blocked to improve the function of these CD4 T cells. In this report, we show that blocking one or two of the molecules involved, called PD-1 and IL-10, has different effects on the individual functions of these cells and that one is strongly improved. We investigate how these effects are caused by interactions between CD4 T cells and antigen-presenting cells. These observations can have implications for new therapeutic approaches in HIV infection.
authors.affiliation: Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Filippos
authors.initials: F
authors.lastname: Porichis
authors.forename: Meghan G
authors.initials: MG
authors.lastname: Hart
authors.forename: Jennifer
authors.initials: J
authors.lastname: Zupkosky
authors.forename: Lucie
authors.initials: L
authors.lastname: Barblu
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Kwon
authors.forename: Ashley
authors.initials: A
authors.lastname: McMullen
authors.forename: Thomas
authors.initials: T
authors.lastname: Brennan
authors.forename: Rafi
authors.initials: R
authors.lastname: Ahmed
authors.forename: Gordon J
authors.initials: GJ
authors.lastname: Freeman
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Kavanagh
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Kaufmann
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000938:Antigen-Presenting Cells / Q000276:immunology* / Q000378:metabolism* / Q000821:virology; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism* / Q000821:virology; D016207:Cytokines / Q000096:biosynthesis; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000378:metabolism; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism*; D053709:Interleukin-10 Receptor alpha Subunit / Q000037:antagonists & inhibitors; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D009000:Monocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D061026:Programmed Cell Death 1 Receptor / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D016207:Cytokines; D018984:Epitopes, T-Lymphocyte; D053709:Interleukin-10 Receptor alpha Subunit; D061026:Programmed Cell Death 1 Receptor; D016753:Interleukin-10; D007371:Interferon-gamma